Financial reports
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
Current reports
8-K
Entry into a Material Definitive Agreement
20 Feb 24
8-K
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
9 Feb 24
8-K
Regulation FD Disclosure
25 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
10 Jan 24
8-K
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating
10 Jan 24
8-K
Regulation FD Disclosure
15 Nov 23
8-K
Regulation FD Disclosure
8 Nov 23
8-K
Entry into a Material Definitive Agreement
29 Sep 23
8-K
Regulation FD Disclosure
22 Sep 23
8-K
Regulation FD Disclosure
23 Aug 23
Registration and prospectus
S-1
IPO registration
19 Apr 24
D/A
$3.30 mm in debt, sold $3.30 mm, 1 investor
21 Feb 24
D
Exempt offering of security
20 Feb 24
S-8
Registration of securities for employees
3 Jul 23
8-A12B/A
Registration of securities on exchange (amended)
12 May 23
424B5
Prospectus supplement for primary offering
19 Apr 23
8-A12B/A
Registration of securities on exchange (amended)
10 Feb 23
8-A12B/A
Registration of securities on exchange (amended)
14 Nov 22
S-8
Registration of securities for employees
1 Jul 22
S-3
Shelf registration
21 Jan 22
Proxies
DFAN14A
Additional proxy materials by non-management
3 Jan 24
DEFA14A
Additional proxy soliciting materials
29 Dec 23
DEFA14A
Additional proxy soliciting materials
28 Nov 23
DEFA14A
Additional proxy soliciting materials
20 Nov 23
DFAN14A
Additional proxy materials by non-management
20 Nov 23
DEFA14A
Additional proxy soliciting materials
20 Nov 23
DFAN14A
Additional proxy materials by non-management
16 Nov 23
DEFA14A
Additional proxy soliciting materials
8 Nov 23
DEFA14A
Additional proxy soliciting materials
7 Nov 23
DEFC14A
Proxy in contested solicitation
6 Nov 23
Other
CORRESP
Correspondence with SEC
24 Oct 23
UPLOAD
Letter from SEC
20 Oct 23
UPLOAD
Letter from SEC
19 Oct 23
UPLOAD
Letter from SEC
26 Sep 22
UPLOAD
Letter from SEC
22 Sep 22
CORRESP
Correspondence with SEC
21 Sep 22
UPLOAD
Letter from SEC
20 Sep 22
EFFECT
Notice of effectiveness
7 Feb 22
CORRESP
Correspondence with SEC
31 Jan 22
UPLOAD
Letter from SEC
26 Jan 22
Ownership